An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0 ...
A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback